Cancer Research Cancer Epigenetics Genetics and Biology of Brain Cancer
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
[Cancer Research 59, 2718-2723, June 1, 1999]
© 1999 American Association for Cancer Research
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ridgway, J. B. B.
Right arrow Articles by Carter, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ridgway, J. B. B.
Right arrow Articles by Carter, P.
[Cancer Research 59, 2718-2723, June 1, 1999]
© 1999 American Association for Cancer Research

Molecular Biology and Genetics

Identification of a Human Anti-CD55 Single-Chain Fv by Subtractive Panning of a Phage Library Using Tumor and Nontumor Cell Lines

John B. B. Ridgway, Eric Ng1, Jeffrey A. Kern2, James Lee, Jennifer Brush, Audrey Goddard and Paul Carter3

Departments of Molecular Oncology [J. B. B. R., E. N., P. C.], Molecular Biology [J. L., J. B., A. G.], and Protein Chemistry [J. A. K.], Genentech Inc., South San Francisco, California 94080


   ABSTRACT
Top
 ABSTRACT
INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
A large naïve human single-chain (sc) Fv phage library was used to search for tumor-associated antigens by panning with a lung adenocarcinoma cell line, 1264, and counter-selecting with a nontumor bronchial epithelial cell line, BEAS-2B. After three rounds of subtractive panning, 239 of 673 clones analyzed bound selectively to 1264 tumor cells in a phage ELISA. Diversity analysis of these tumor-selective clones by BstNI fingerprinting and nucleotide sequencing revealed 14 distinct scFv fragments. Four clones bound selectively to 1264 over BEAS-2B cells when analyzed by a more discriminating flow cytometric assay using scFv. Moreover, these clones showed only limited cross-reactivity to several primary human cell lines. One clone, LU30, also cross-reacted strongly with the lung adenocarcinoma line, A549. The LU30 antigen was identified as decay-accelerating factor (CD55) by expression cloning from a 1264 cDNA library. The mean number of decay-accelerating factor molecules on the surface of 1264 and BEAS cells used for panning and counter-selection was estimated as 75,000 ± 5,000 and 13,000 ± 10,000, respectively. Thus, phage library panning combined with expression cloning permits identification of antibodies and their cognate antigens for proteins that are differentially expressed on the surface of distinct cell populations.


   INTRODUCTION
Top
 ABSTRACT
 INTRODUCTION
MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
The demonstration of significant antitumor efficacy of antibodies has long been sought-after in the clinic and recently obtained using naked chimeric (1, 2, 3, 4) and humanized (5) antibodies, as well as with radiolabeled murine antibodies (6, 7, 8, 9) . Indeed, a chimeric anti-CD20 antibody (10) and a humanized anti-HER2 antibody (11) were approved recently by the United States Federal Drug Administration for the treatment of non-Hodgkin’s lymphoma and metastatic breast cancer, respectively. These successes with antitumor antibodies in patients has led to renewed interest in the identification of novel tumor-associated antigens suitable for antibody targeting.

The traditional approach to obtaining tumor-specific antibodies has been to immunize mice with tumor cells and to screen the resultant monoclonal antibodies for their binding specificity. Unfortunately, tumor-binding antibodies obtained in this way often cross-react with many normal cells, which may interfere with their clinical use. Ideally, one would like to select rather than screen for antibodies that bind selectively to tumor. The advent of antibody fragment display on phage (12) and the development of large (>6 x 109 clones) phage display libraries (13, 14, 15) offer a potential way of doing this by panning using tumor cells and counter-selecting using nontumor cells. An additional advantage of antibody phage is that, unlike hybridoma technology, it is readily possible to obtain antibodies binding antigens that are highly conserved between mouse and man (16) .

Naïve antibody phage libraries have proved to be a rapid and general method for identifying antibodies binding to purified antigens (13, 14, 15, 16) . In contrast, panning cellular targets with antibody phage has proved much more difficult because of the much lower effective antigen concentration, greater antigen complexity, and the tendency of phage to bind nonspecifically to cells. Nevertheless, significant progress has been made, allowing the identification of antibodies against cell surface antigens (17, 18, 19, 20, 21, 22, 23) . Indeed, melanoma-specific antibodies have been identified by selecting for antibody phage that bind to melanoma cells, but not melanocytes, using antibody phage libraries constructed from human donors immunized with their own tumor cells (21, 22, 23) .

We have extended the use of antibody phage libraries for panning on live tumor cells by using a large naïve library (14) . This obviates the need for creating custom libraries from immunized donors (21 , 23) . In addition, live rather than fixed cells (21, 22, 23) were used for screening to facilitate the identification of antibodies that bind to native rather than denatured antigens. This was done to facilitate subsequent expression cloning of corresponding antigen, as well as enhance the therapeutic potential of antibodies obtained. Indeed, we cloned the antigen corresponding to a scFv4 fragment identified with significant tumor selectivity.


   MATERIALS AND METHODS
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
RESULTS
 DISCUSSION
 REFERENCES
 
Cell Lines.
The lung adenocarcinoma line 1264 was kindly provided by Dr. A. Gazdar (Simmons Cancer Center, University of Texas-Southwestern, Dallas, TX) and grown in RPMI 1640 supplemented with 10% (v/v) FBS. The lung adenocarcinoma cell lines SKLU1, A549, and CALU6 were obtained from American Type Culture Collection (Manassas, VA) and grown in a 1:1 mixture of RPMI 1640 and DMEM supplemented with 10% (v/v) FBS. The BEAS-2B cell line, constructed by SV40 transformation of human bronchial epithelial cells, was obtained from American Type Culture Collection, as was CCD19LU, a fibroblast-like cell line isolated from normal human lung. Both BEAS-2B and CCD19LU cells were cultured in RPMI/DMEM/FBS. NHBE 4683 and NHEK 4021 are primary cell lines (Clonetics, San Diego, CA) that were cultured in the serum-free media, BEGM and KGM (Clonetics), respectively. NHBE 4683 and NHEK 4021 lines were used for subtractive panning or analysis between the third and fourth passage. All cell lines were grown adherently and detached with 2.5 mM EDTA in PBS before use.

Live Cell Panning with scFv Phage.
An aliquot containing 2.5 x 1012 cfu phage, from a large human scFv phage library (14) was blocked with 500 µl of RPMI containing 10% (v/v) FBS, 1 mM phenylmethylsulfonyl fluoride, and 2.5 mM EDTA to reduce nonspecific binding to cell surfaces. The blocked phage were added to 1 x 106 BEAS-2B cells in 500 µl of RPMI/DMEM/FBS and mixed gently for 30 min at ~20°C. Cells were then pelleted, at this and subsequent panning steps, by centrifugation at 500 x g for 5 min at 4°C. The phage-containing supernatant was used to resuspend a fresh pellet of 1 x 106 BEAS-2B cells and was incubated for 30 min at ~20°C, followed by pelleting the cells. After repeating this counter-selection step, the resultant "subtracted" phage supernatant was incubated with 5 x 106 1264 cells for 1 h at ~20°C with gentle mixing. The cells were pelleted and washed three times with PBS. The cell-bound phage were eluted with 0.5 ml of PBS containing 100 mM citric acid (pH 2.2) for 10 min and then neutralized with 0.5 ml of 1.0 M Tris-HCl (pH 7.5).

Escherichia coli strain TG1 (New England Biolabs, Beverly, MA) in mid-logarithmic growth phase (A550 = 0.4–0.8) was infected with the eluted phage and plated on 2YT agar containing 2% (w/v) glucose and 50 µg/ml carbenicillin (2YTGC). The resultant colonies were propagated and used to prepare phage (24) . An aliquot containing ~1 x 1012 cfu phage was used for a second round of panning, consisting of five counter-selections using 1 x 106 BEAS-2B cells, followed by selection using 1 x 107 1264 cells for ~15 h at ~20°C. After 10 washes with PBS, the cell-bound phage were eluted and then neutralized as in the first round of panning. The eluted phage were propagated, and a third round of panning was performed using 1.0 x 1012 cfu phage and the second round protocol.

Cell ELISA with Phage.
The scFv-phage were compared in their binding to live tumor and nontumor cells by ELISA as a primary screen of their binding specificity. After the third round of panning, a culture of TG1 was infected with the eluted phage and plated on 2YTGC. Clones for analysis were transferred into 96-well plates with 100 µl of 2YT media containing 2% (w/v) glucose and carbenicillin (100 µg/ml) and grown for ~18 h with agitation at 30°C. Glycerol (50 µl 50%, v/v) was added to each well of these master plates before storage at -70°C.

Replicas of the master plates were prepared, and scFv-phage were induced by superinfection with M13KO7 helper phage and overnight incubation at 30°C (24) . The plates were centrifuged (300 x g, 5 min, 4°C) at this and subsequent cell ELISA steps to pellet the bacteria, and 100 µl of scFv-phage-containing supernatants were transferred to 96-well plates containing 100 µl of 6% (w/v) BSA in PBS/well. Blocked scFv-phage supernatants (100 µl) were added to parallel plates containing either 1 x 105 1264 or BEAS-2B cells/well (1 h, 4°C, gentle agitation). The plates were centrifuged, and supernatants were aspirated without disturbing the pellets. The cells were washed twice by resuspension in 200 µl of 4% (v/v) FBS in PBS (ELISA buffer) at 4°C, followed by centrifugation. Pellets were then resuspended in 100 µl of ELISA buffer containing a 1:5,000 dilution of horseradish peroxidase conjugated to a sheep anti-M13 polyclonal (Amersham Pharmacia Biotech, Piscataway, NJ) and incubated for 20 min at 4°C. Cells were centrifuged and washed three times in ELISA buffer. Cell pellets were resuspended in 100 µl of TMB reagents (Kirkegaard and Perry Laboratories, Inc., Gaithersburg, MD) and developed for ~10 min before quenching with 100 µl of 1 M phosphoric acid. The ELISA plates were read (A450-A650) using a Spectramax 340 microtiter plate reader (Molecular Devices, Sunnyvale, CA), and data were analyzed using a spreadsheet program (Microsoft Excel 5.0a).

Flow Cytometry with Phage and scFv.
Culture supernatants containing scFv phage were incubated with cells and washed, as described above, for the cell ELISA with the following modifications. The anti-M13 polyclonal antibody was used in unconjugated form. After washing, the cells were incubated for 20 min at 4°C with an R-phycoerythin-conjugated F(ab')2 fragment from a donkey antisheep IgG (Jackson Immunoresearch Laboratories, West Grove, PA) diluted 1:200 in ELISA buffer, followed by three washes and resuspension in 0.5 ml of ELISA buffer. Cells were analyzed using a FACScan flow cytometer (Beckton and Dickinson, Mountain View, CA).

For cytometric analysis with scFv fragments, 1 x 105 cells in ELISA buffer were incubated for 1 h at 4°C with 3 µg/ml scFv fragment. The cells were washed twice by centrifugation and resuspension in ELISA buffer. Cell pellets were then resuspended in 100 µl of ELISA buffer containing 1 µg/ml BMG-His1 (Boehringer Mannheim, Indianapolis, IN), the antihexahistidine monoclonal antibody. Cells were washed three times in ELISA buffer before resuspension in 100 µl of ELISA buffer containing a 1:200 dilution of a F(ab')2 fragment of a goat antimouse IgG conjugated with FITC (Jackson Immunoresearch Laboratories). After three additional washes, the cells were analyzed by flow cytometry.

Quantitation of Cell Surface DAF.
The mean number of DAF molecules/cell was estimated by flow cytometry using a FITC-labeled antibody in comparison with FITC-conjugated beads, using the method of Christensen and Leslie (25) , with the following modifications. Murine anti-DAF monoclonal antibody 1A10 (250 µg; Genentech Inc.) in 50 mM sodium carbonate (pH 8.5) was incubated with 12 µg of N-hydroxysuccinimidyl-fluorescein (Pierce Chemical Co., Rockford, IL) for 2 h at 20°C, followed by extensive dialysis against PBS. The molar ratio of FITC to protein was determined from the absorbance at 280 nm and 492 nm (25) . Cells were incubated with varying levels of the FITC-labeled anti-DAF antibody to achieve saturation and then prepared for flow cytometry, as above.

Clone Diversity Analysis.
The diversity of antigen-positive clones was analyzed by PCR-amplification of the scFv insert using the primers fdtetseq and PUC19 reverse (16) , digestion with BstNI (24) , and analysis by PAGE. Comparison of BstNI fingerprints was facilitated by digitization of the gel data using an AlphaImager (Alpha Innotech Corp., San Leandro, CA) and analysis using ProRFLP version 2.34 (DNA ProScan, Nashville, TN). Up to 10 clones/BstNI fingerprint were then cycle-sequenced using rhodamine-labeled dideoxy chain terminators (Applied Biosystems, Foster City, CA), using M13 reverse (New England Biolabs) and mycseq10 primers (16) . Samples were analyzed using Applied Biosystems Automated DNA Sequencers (models 373 and 377), and sequence data were analyzed using the program Sequencher version 3.1 (Gene Codes Corp., Ann Arbor, MI).

scFv Production.
Selected scFv clones were transformed into E. coli strain 33D3 (W3110 tonA ptr3 phoA{Delta}E15 lacIqlacL8 degP kanR; Ref. 26 ) and cultured for 18 h at 30°C in 2YT media containing 0.2 mM isopropyl-ß-D-galactopyranoside to induce scFv expression. Periplasmic extracts were prepared by resuspending a bacterial pellet from a 500-ml culture in 10 ml of 50 mM sodium phosphate buffer (pH 8.0) containing 0.5 M NaCl, 25 mM imidazole, 0.2 mg/ml hen egg white lysozyme, and 1 mM phenylmethylsulfonyl fluoride. After incubation for 1 h at 4°C, the debris was removed by centrifugation. Supernatants were filtered (0.2 µm) and, the His-tagged scFv fragments were purified by immobilized metal affinity chromatography using Ni2+-nitrilotriacetic acid agarose (Qiagen, Valencia, CA). The scFv fragments were eluted with 250 mM imidazole in PBS, then dialyzed into PBS, flash frozen, and stored at -70°C. Clones LU1, LU4, LU13, LU20, and LU30 were grown to high cell density in the fermenter, as described previously (27) . scFv fragments were purified from 2 g of fermentation pastes, as for cell pellets from shake flasks.

cDNA Library Construction.
Total cellular RNA was purified from guanidine thiocyanate homogenates from 6 g of cultured 1264 cells (28) . mRNA was isolated from the total RNA using oligo-d(T) cellulose (Collaborative Research, Bedford, MA; Ref. 29 ). Oriented cDNA transcripts were prepared from 5 µg of poly(A)+ mRNA using the SuperScript Plasmid System (Life Technologies, Inc., Gaithersburg, MD), fractionated by electrophoresis on a 5% polyacrylamide gel, and size selected in the ranges of 0.6–2.0 kb and >2 kb. Eluted cDNAs were ligated into the XhoI and NotI sites of the mammalian expression vector pRK5 (30) and then electroporated into DH10B (Life Technologies, Inc.) cells under conditions recommended by the supplier.

Antigen Expression Cloning from cDNA Library.
DNA from 10 pools of 50,000 clones each of the 0.6–2 kb and >=2 kb cDNA libraries was prepared for expression cloning the antigens recognized by tumor-selective scFv fragments. Plasmid DNA (10 µg) from each of the 20 pools was electroporated into 2 x 106 COS7 cells in 180 µl of PBS using 4-mm gap cuvettes with a Gene Pulser electroporator (Bio-Rad, Hercules, CA) with an applied voltage of 300 V and a capacitance of 125 µF. After incubation for 72 h at 37°C, the COS7 cells were detached with 2.5 mM EDTA in PBS. The cells were washed and then incubated in 1 ml of growth media containing one or more purified scFv fragment (10 µg/ml each) for 1 h at 4°C. The cells were washed twice to remove unbound scFv, resuspended in 1 ml of media containing 5 µg of anti-penta-histidine antibody (Qiagen) and incubated for 1 h at 4°C. After two to three washes, the cells were resuspended in 5 ml of media and transferred to a polystyrene dish coated with a polyclonal antimouse IgG (ICN/Cappel, Aurora, OH) and allowed to bind for 1 h at 4°C. Plates were washed gently three to four times with PBS. Remaining attached cells were lysed, plasmid DNA-extracted, and amplified (31) . This DNA was then electroporated into COS7 cells for additional panning. In one case, an increasing number of cells were captured during the second to fourth rounds of panning. Plasmid DNA extracted from the COS7 cells was transformed into TG1, and single colonies were picked into 96-well plates. DNA was prepared from pools of 10–20 clones each, electroporated into COS7 cells, and panned with scFv fragments, as described above. Pools of clones positive for cells binding to the Petri dishes were broken down from the E. coli master plates, and individual clones were tested by panning. An individual positive clone was cycle-sequenced using rhodamine-labeled dideoxy chain terminators.

Affinity Measurements.
Kinetic measurements were made by surface plasmon resonance using a Biacore 1000 Biosensor (Biacore, AB Uppsala, Sweden). CM-5 chips were functionalized with 350 response units of recombinant human DAF in 10 mM sodium acetate (pH 4.6) or 8000 response units of BSA as a negative control. The DAF-derivatized chip was saturated with LU30 scFv (25–100 nM) by injecting this fragment at 10 µl/min in PBS containing 0.5% (w/v) BSA and 0.05% (v/v) Tween 20. The resultant sensorgrams were analyzed using BIAevaluation software 3.0.


   RESULTS
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
DISCUSSION
 REFERENCES
 
Subtractive Cellular Panning with scFv Phage.
A large human scFv-phage library (14) was used to search for novel tumor-associated antigens by panning with the lung adenocarcinoma cell line 1264 and counter-selecting with the nontumor bronchial epithelial cell line BEAS-2B. Precautions were taken to maintain the integrity of membrane antigens during panning to facilitate subsequent identification of antigen by expression-cloning using isolated scFv fragments. First, live rather than fixed cells were used for panning in an attempt to preserve surface antigens in their native state. Second, cells grown adherently were detached with EDTA alone, thereby avoiding proteolytic degradation of cell surface antigens resulting from the commonly used trypsin release step.

The number of phage recovered after one, two, and three rounds of panning was 1.5 x 107, 7.0 x 105, and 4.0 x 106 cfu, respectively. The phage populations after each round of panning were analyzed by flow cytometry. The phage from the third round showed a large increase in binding to 1264 cells and a slightly smaller increase with BEAS-2B cells when compared with phage from prior rounds and unselected phage (Fig. 1)Citation . This apparent differential increase in binding to 1264 over BEAS-2B cells encouraged us to screen individual phage from the third round population for selective binding to the 1264 tumor cells.



View larger version (25K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 1. Flow cytometric analysis of phage populations from Rounds 1, 2, and 3 binding to tumor cell line 1264 (black) used for selection and nontumor line BEAS-2B (gray) used for counter-selection. Also shown is a negative control phage population.

 
Analysis of Clone Specificity and Diversity.
The binding specificity of individual clones from the third round of panning was analyzed by ELISA using scFv-phage and live cells. The primary criteria used to assess tumor-selectivity were robust binding to 1264 cells (A450-A650 >= 0.3) and much weaker if detectable binding to BEAS-2B cells (>=10-fold lower ELISA signal). The diversity of clones satisfying these primary criteria was assessed by BstNI fingerprinting of the PCR-amplified scFv fragments, and nucleotide sequencing of up to 10 clones/fingerprint pattern. A small number of clones that did not satisfy the primary criteria were also fingerprinted (n = 29) and sequenced (n = 11). Secondary criteria were then used to choose unique and apparently tumor-selective clones for further analysis: (a) open reading frame for scFv; and (b) majority of clones that share the same nucleotide sequence also satisfy the primary selection criteria.

As anticipated, the majority of clones assayed show detectable binding to 1264 cells by phage ELISA, many with limited cross-reactivity to BEAS-2B cells (Fig. 2)Citation . Of 673 clones analyzed, 239 satisfied the primary criteria for selective binding, and 197 clones could be assigned to 15 different BstNI fingerprint patterns (Table 1)Citation . In the majority of cases (13 of 15), one fingerprint pattern gave rise to a single nucleotide sequence, whereas in 2 of 15 cases, two different sequences were found with indistinguishable BstNI fingerprint patterns. Thus, a total of 17 scFv clones that satisfy the secondary selection criteria were identified. The two most abundant clones, fingerprints types 1 and 2, represented ~80% of the clones satisfying the secondary criteria. In contrast, the other 15 clones each represent <=5% of the clones identified. Four of the 17 clones (LU1, LU3, LU22, and LU36) are so closely related (>=97% amino acid identity for scFv; Fig. 3ACitation ) that they were considered to be four variants of one distinct scFv. Thus, from the 673 clones initially screened, 14 distinct scFv clones were identified that show selective binding to 1264 cells as judged by phage ELISA. These 14 distinct scFv fragments have divergent VH sequences (Fig. 3B)Citation , whereas their corresponding VL domains are more limited in diversity (Fig. 3C)Citation . Indeed, many of the scFv clones isolated use identical or very closely related VL sequences as, noted previously (14 , 32) . This reflects the very limited size of the light chain repertoire in the phage library.



View larger version (23K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 2. ELISA screening of scFv phage binding to 1264 and BEAS-2B cells. Highlighted clones (*) satisfy the primary criteria for tumor selectivity: A450-A650 >=0.3 for binding to 1264 cells and >=10-fold lower signal with BEAS-2B cells. Identified clones (arrows) bind 1264 cells with minimal cross-reactivity to BEAS-2B cells in a stringent flow cytometric assay using purified scFv fragments (see "Results"). Data are sorted by the ELISA signal with 1264 cells and are taken from a representative 96-well plate.

 

View this table:
[in this window]
[in a new window]

  		Table 1 Primary screening of scFv phage clones

 


View larger version (17K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 3. Dendrograms for tumor-selective scFv satisfying primary and secondary selection criteria (see Table 1Citation ). Comparisons were made between scFv amino acid sequences (A), as well as their component VH domains (B), and VL domains (C).

 
Stringent Analysis of Clone Specificity.
The 14 distinct clones that satisfied the secondary selection criteria (Table 1)Citation were further analyzed by a more discriminating, but low, throughput flow cytometric screen using scFv fragments (representative data in Fig. 4Citation ). Four clones, namely LU1, LU13, LU20, and LU30, demonstrated significant binding to 1264 cells, but minimal cross-reactivity to BEAS-2B cells. In contrast, the remaining clones (represented by LU4 in Fig. 4Citation ) showed significant cross-reactivity to BEAS-2B. Clone LU30, which gave the most pronounced binding to 1264, also gave strong staining of one of three additional lung adenocarcinoma lines tested (A549). Clones LU1, LU13, LU20, and LU30 showed minimal cross-reactivity to BEAS-2B and the primary human line NHEK 4021 (Fig. 4)Citation . Flow cytometric analysis with the primary human lines CCD-19LU and NHBE 4683 gave very similar binding between LU1, LU13, LU20, and LU30 phage as control phage, albeit with substantially higher background binding than for the other lines (data not shown).



View larger version (33K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 4. Flow cytometric analysis of scFv fragments with tumor (1264, A549, CALU6, and SKLU1) and nontumor (BEAS-2B and NHEK) cell lines.

 
Expression Cloning of LU30 Antigen.
ScFv fragments corresponding to clones LU13, LU20, and LU30 were prepared by secretion from E. coli and immobilized metal affinity chromatography and used for expression cloning. Panning was performed using a mixture of these three scFv fragments, and a cDNA expression library was constructed from 1264 cells that was transiently expressed in COS7 cells. After three rounds of panning using a mixture of these three scFv fragments, efficient cell capture was demonstrated with some plasmid pools using LU30, but not LU13 and LU20 scFv fragments. Repeated panning using clones LU13 and LU20 in the absence of LU30 was also unsuccessful. Positive pools for clone LU30 were broken down first into smaller pools and then into individual clones. This led to the identification of a single clone expressing a protein that bound specifically to the LU30 scFv fragment. Nucleotide sequence analysis of this clone identified it as DAF (CD55). Binding of LU30 scFv (GenBank accession number AF117206) to 1264 cells could be competed with recombinant human DAF (Fig. 5)Citation , but not with the anti-DAF monoclonal antibody 1A10 (data not shown). Further confirmation of LU30 binding to DAF was provided by affinity measurements obtained using a BIAcore instrument: , , .



View larger version (16K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 5. Binding of LU30 scFv (3 µg/ml) to 1264 cells in the absence and presence of recombinant human DAF (30 µg/ml).

 
Cellular DAF Levels.
The mean number of DAF molecules on 1264 and BEAS-2B cell lines was estimated by quantitative flow cytometry using an anti-DAF IgG labeled with a mean number of 5.3 FITC molecules in comparison with standards. The number of DAF molecules on the 1264 tumor cells used for panning and BEAS nontumor cells used for counter-selection was estimated as 75,000 ± 5,000 and 13,000 ± 10,000, respectively. Attempts to estimate the number of DAF sites on BEAS-2B and 1264 using this methodology with the LU30 scFv fragment were unreliable because FITC labeling of LU30 scFv impaired its binding to DAF.


   DISCUSSION
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
REFERENCES
 
We have identified four scFv fragments that bind more extensively to one or more tumor cell lines than to related nontumor cell lines by subtractive panning of live cells with a large naïve antibody phage library. The cognate antigen corresponding to one scFv clone, LU30, was identified as DAF by expression cloning. DAF is expressed at ~6-fold greater levels on 1264 cells than BEAS cells used for counter-selection. Thus, the counter-selection process is not 100% efficient, permitting identification of a scFv fragment that binds to antigen that is present at much higher levels on target than control cells. This bodes well for the use of this method because cell surface antigens that are overexpressed in tumors compared with normal tissues occur frequently [e.g., HER2/neu (33) and epidermal growth factor receptor (34) ]. Antigens that are present in tumors but absent from normal tissues have been much sought after, but have, thus far, proved elusive.

The LU30 antigen DAF is a glycophosphatidylinositol-anchored protein that acts together with two other glycophosphatidylinositol-anchored proteins, CD46 and CD59, in protecting host cells from complement-mediated cell lysis (35) . DAF is expressed at widely varying levels on tumor cell lines, and its overexpression correlates with enhanced resistance to complement-mediated cell lysis in vitro (36) . DAF overexpression has been observed on a variety of human tumor tissues including six of nine lung adenocarcinomas and two of seven lung squamous cell carcinomas (37) . Nevertheless, DAF seems poorly suited as a target for tumor immunotherapy because it is broadly expressed on the surface of normal cells, particularly those exposed to serum complement (35) . Regarding normal lung tissue, DAF has been detected by immunohistochemistry on the alveolar epithelium, interstitium, and endothelium, as well as the bronchial epithelium, glands and ducts, and also blood vessels (37) .

Antibody phage panning method offers a potential direct and broadly applicable route to the identification of human antibodies suitable for antitumor therapy. This strategy likely favors the identification of antibodies to highly expressed antigens, such as DAF shown here, because high antigen levels are anticipated to facilitate enrichment of cognate-scFv phage during panning. This seems desirable because high-level antigen expression may also facilitate tumor localization of antitumor antibodies in vivo.

Antibody phage panning could potentially identify tumor-associated antigens resulting from posttranslational modifications that differ between tumor and nontumor cells [e.g., the mucin product of the MUC1 gene is underglycosylated in many human tumors (38) exposing new epitopes for antibody targeting]. This has prompted the development of humanized anti-MUC1 antigen (39, 40, 41) . Furthermore, human antibodies recognizing MUC1 on tumor cells have been identified by panning with a MUC1 peptide (42) . In contrast, such posttranslational differences between tumor and nontumor cells will not be detected by powerful high throughput transcriptome and genomic methods, such as differential display (43) cDNA (44 , 45) or oligonucleotide (46) microarray and serial analysis of gene expression (47, 48, 49) . Transcriptome and genomic methods will also fail to detect proteins which are overexpressed in tumors despite unchanged RNA transcript levels and gene copy number, respectively.

Serial analysis of gene expression has identified significant differences in RNA transcript levels between primary human tumors and tumor cells lines (48) . This raises the possibility that antibody phage panning may fail to detect tumor-associated antigens found on primary human tumors, but absent on cell lines. Conversely, antibodies may be identified that are cell line-specific as judged by failure to bind primary human tumor cells. Direct panning on primary human tumor cells is anticipated to avoid these problems, but entails as yet unaddressed technical challenges. Credence to the notion that these obstacles are surmountable is provided by reports of successful panning with peptide phage libraries in vivo (50, 51, 52) .


   ACKNOWLEDGMENTS
 
We thank Peter Schow for flow cytometric analysis, Paul Moran for providing recombinant human DAF, and Jim Ligos for help in preparing figures.


   FOOTNOTES
 
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1 Present address: Rush Medical College, Chicago, IL 60612. Back

2 Present address: University of Iowa College of Medicine, Department of Internal Medicine, Iowa City, IA 52242. Back

3 To whom requests for reprints should be addressed, at Genentech Inc., 1 DNA Way, South San Francisco, CA 94080. Phone: (650) 225-1932; Fax: (650) 225-1716; E-mail: pjc{at}gene.com Back

4 The abbreviations used are: scFv, single-chain Fv; DAF, decay-accelerating factor; FBS, fetal bovine serum; cfu, colony-forming unit; NHBE, normal human bronchial epithelial; NHEK, normal human epidermal keratinocyte. Back

Received 1/18/99. Accepted 4/ 1/99.


   REFERENCES
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 

  1. Riethmüller G., Schneider-Gädicke E., Schlimok G., Schmiegel W., Raab R., Höffken K., Gruber R., Pichlmaier H., Hirche H., Pichlmayr R., Buggisch P., Witte J., the German Cancer Aid 17-1A Study Group. Randomized trial of monoclonal antibody for adjuvant therapy of resected Dukes’ C colorectal carcinoma. Lancet, 343: 1177-1183, 1994.[Medline]
  2. Riethmüller G., Holz E., Schlimok G., Schmiegel W., Raab R., Höffken K., Gruber R., Funke I., Pichlmaier H., Hirche H., Buggisch P., Witte J., Pichlmayr R. Monoclonal antibody therapy for resected Dukes’ C colorectal cancer: seven-year outcome of a multicenter randomized trial. J. Clin. Oncol., 16: 1788-1794, 1998.[Abstract]
  3. Maloney D. G., Grillo-López A. J., White C. A., Bodkin D., Schilder R. J., Neidhart J. A., Janakiraman N., Foon K. A., Liles T. M., Dallaire B. K., Wey K., Royston I., Davis T., Levy R. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin’s lymphoma. Blood, 90: 2188-2195, 1997.[Abstract/Free Full Text]
  4. McLaughlin P., Grillo-López A. J., Link B. K., Levy R., Czuczman M. S., Williams M. E., Heyman M. R., Bence-Bruckler I., White C. A., Cabanillas F., Jain V., Ho A. D., Lister J., Wey K., Shen D., Dallaire B. K. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J. Clin. Oncol., 16: 2825-2833, 1998.[Abstract]
  5. Baselga J., Tripathy D., Mendelsohn J., Baughman S., Benz C. C., Dantis L., Sklarin N. T., Seidman A. D., Hudis C. A., Moore J., Rosen P. P., Twaddell T., Henderson I. C., Norton L. Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J. Clin. Oncol., 14: 697-699, 1996.[Free Full Text]
  6. Press O. W., Eary J. F., Appelbaum F. R., Martin P. J., Badger C. C., Nelp W. B., Glenn S., Butchko G., Fisher D., Porter B., Matthews D. C., Fisher L. D., Bernstein I. D. Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support. N. Engl. J. Med., 329: 1219-1224, 1993.[Abstract/Free Full Text]
  7. Press O. W., Eary J. F., Appelbaum F. R., Martin P. J., Nelp W. B., Glenn S., Fisher D. R., Porter B., Matthews D. C., Gooley T., Bernstein I. D. Phase II trial of 131I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas. Lancet, 346: 336-340, 1995.[Medline]
  8. Kaminski M. S., Zasadny K. R., Francis I. R., Milik A. W., Ross C. W., Moon S. D., Crawford S. M., Burgess J. M., Petry N. A., Butchko G. M., Glenn S. D., Wahl R. D. Radioimmunotherapy of B-cell lymphoma with [131I]anti-B1 (anti-CD20) antibody. N. Engl. J. Med., 329: 459-465, 1993.[Abstract/Free Full Text]
  9. Kaminski M. S., Zasadny K. R., Francis I. R., Fenner M. C., Ross C. W., Milik A. W., Estes J., Tuck M., Regan D., Fisher S., Glenn S. D., Wahl R. L. Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma. J. Clin. Oncol., 14: 1974-1981, 1996.[Abstract/Free Full Text]
  10. Reff M. E., Carner K., Chambers K. S., Chinn P. C., Leonard J. E., Raab R., Newman R. A., Hanna N., Anderson D. R. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood, 83: 435-445, 1994.[Abstract/Free Full Text]
  11. Carter P., Presta L., Gorman C. M., Ridgway J. B. B., Henner D., Wong W. L. T., Rowland A. M., Kotts C., Carver M. E., Shepard H. M. Humanization of an anti-p185 HER2 antibody for human cancer therapy. Proc. Natl. Acad. Sci. USA, 89: 4285-4289, 1992.[Abstract/Free Full Text]
  12. McCafferty J., Griffiths A. D., Winter G., Chiswell D. J. Phage antibodies: filamentous phage displaying antibody variable domains. Nature (Lond.), 348: 552-554, 1990.[Medline]
  13. Griffiths A. D., Williams S. C., Hartley O., Tomlinson I. M., Waterhouse P., Crosby W. L., Kontermann R., Jones P. T., Low N. M., Allison T. J., Prospero T. D., Hoogenboom H. R., Nissim A., Cox J. P. L., Harrison J. L., Zaccolo M., Gherardi E., Winter G. Isolation of high affinity human antibodies directly from large synthetic repertoires. EMBO J., 13: 3245-3260, 1994.[Medline]
  14. Vaughan T. J., Williams A. J., Pritchard K., Osbourn J. K., Pope A. R., Earnshaw J. C., McCafferty J., Hodits R. A., Wilton J., Johnson K. S. Human antibodies with sub-nanomolar affinities isolated from a large non-immunized phage display library. Nat. Biotechnol., 14: 309-314, 1996.[Medline]
  15. Sheets M. D., Amersdorfer P., Finnern R., Sargent P., Lindqvist E., Schier R., Hemingsen G., Wong C., Gerhart J. C., Marks J. D. Efficient construction of a large nonimmune phage antibody library: the production of high-affinity human single-chain antibodies to protein antigens. Proc. Natl. Acad. Sci. USA, 95: 6157-6162, 1998.[Abstract/Free Full Text]
  16. Nissim A., Hoogenboom H. R., Tomlinson I. M., Flynn G., Midgley C., Lane D., Winter G. Antibody fragments from a "single pot" phage. EMBO J., 13: 692-698, 1994.[Medline]
  17. Marks J. D., Ouwehand W. H., Bye J. M., Finnem R., Gorick B. D., Voak D., Thorpe S. J., Hughes-Jones N. C., Winter G. Human antibody fragments specific for human blood group antigens from a phage display library. Bio/Technology, 11: 1145-1149, 1992.
  18. Portolano S., McLachlan S. M., Rapoport B. High affinity, thyroid-specific human autoantibodies displayed on the surface of filamentous phage use V genes similar to other autoantibodies. J. Immunol., 151: 2839-2851, 1993.[Abstract]
  19. de Kruif J., Terstappen L., Boel E., Logtenberg T. Rapid selection of cell subpopulation-specific human monoclonal antibodies from a synthetic phage antibody library. Proc. Natl. Acad. Sci. USA, 92: 3938-3942, 1995.[Abstract/Free Full Text]
  20. Van Ewijk W., de Kruif J., Germeraad W. T., Berendes P., Ropke C., Platenburg P. P., Logtenberg T. Subtractive isolation of phage-displayed single-chain antibodies to thymic stromal cells by using intact thymic fragments. Proc. Natl. Acad. Sci. USA, 94: 3903-3908, 1997.[Abstract/Free Full Text]
  21. Cai X., Garen A. Anti-melanoma antibodies from melanoma patients immunized with genetically modified autologous tumor cells: selection of specific antibodies from single-chain Fv fusion phage libraries. Proc. Natl. Acad. Sci. USA, 92: 6537-6541, 1995.[Abstract/Free Full Text]
  22. Cai X., Garen A. A melanoma-specific VH antibody cloned from a fusion phage library of a vaccinated melanoma patient. Proc. Natl. Acad. Sci. USA, 93: 6280-6285, 1996.[Abstract/Free Full Text]
  23. Cai X., Garen A. Comparison of fusion phage libraries displaying VH or single-chain Fv antibody fragments derived from the antibody repertoire of a vaccinated melanoma patient as a source of melanoma-specific targeting molecules. Proc. Natl. Acad. Sci. USA, 94: 9261-9266, 1997.[Abstract/Free Full Text]
  24. Marks J. D., Hoogenboom H. R., Bonnert T. P., McCafferty J., Griffiths A. D., Winter G. By-passing immunization. Human antibodies from V-gene libraries displayed on phage. J. Mol. Biol., 222: 581-597, 1991.[Medline]
  25. Christensen J., Leslie R. G. Q. Quantitative measurement of Fc receptor activity on human peripheral blood monocytes and the monocyte-like cell line, U937, by laser flow cytometry. J. Immunol. Methods, 132: 211-219, 1990.[Medline]
  26. Atwell S., Ridgway J. B. B., Wells J. A., Carter P. Stable heterodimers from remodeling the domain interface of a homodimer using a phage display library. J. Mol. Biol., 270: 26-35, 1997.[Medline]
  27. Carter P., Kelley R. F., Rodrigues M. L., Snedecor B., Covarrubias M., Velligan M. D., Wong W. L. T., Rowland A. M., Kotts C. E., Carver M. E., Yang M., Bourell J. H., Shepard H. M., Henner D. High level Escherichia coli expression and production of a bivalent humanized antibody fragment. Bio/Technology, 10: 163-167, 1992.[Medline]
  28. Chirgwin J. M., Przybyla A. E., MacDonald R. J., Rutter W. J. Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease. Biochemistry, 18: 5294-5299, 1979.[Medline]
  29. Aviv H., Leder P. Purification of biologically active globin messenger RNA by chromatography on oligothymidylic acid-cellulose. Proc. Natl. Acad. Sci. USA, 69: 1408-1412, 1972.[Abstract/Free Full Text]
  30. Suva L. J., Winslow G. A., Wettenhall R. E., Hammonds R. G., Moseley J. M., Diefenbach-Jagger H., Rodda C. P., Kemp B. E., Rodriguez H., Chen E. Y., Hudson P. J., Martin T. J., Wood W. I. A parathyroid hormone-related protein implicated in malignant hypercalcemia: cloning and expression. Science (Washington DC), 237: 893-896, 1987.[Abstract/Free Full Text]
  31. Seed B., Aruffo A. Molecular cloning of the CD2 antigen, the T-cell erythrocyte receptor, by a rapid immunoselection procedure. Proc. Natl. Acad. Sci. USA, 84: 3365-3369, 1987.[Abstract/Free Full Text]
  32. Merchant A. M., Zhu Z., Yuan J. Q., Goddard A., Adams C. W., Presta L. G., Carter P. An efficient route to human bispecific IgG. Nat. Biotechnol., 16: 677-681, 1998.[Medline]
  33. Tzahar E., Yarden Y. The ErbB-2/HER2 oncogenic receptor of adenocarcinomas: from orphanhood to multiple stromal ligands. Biochim. Biophys. Acta, 1377: M25-M37, 1998.[Medline]
  34. Voldborg B. R., Damstrup L., Spang-Thomsen M., Poulsen H. S. Epidermal growth factor receptor (EGFR) and EGFR mutations, function and possible role in clinical trials. Ann. Oncol., 8: 1197-1206, 1997.[Abstract/Free Full Text]
  35. Nicholson-Weller A., Wang C. E. Structure and function of decay-accelerating factor. J. Lab. Clin. Med., 123: 485-491, 1994.[Medline]
  36. Cheung N-K. V., Walter E. I., Smith-Mensah W. H., Ratnoff W. D., Tykocinski M. L., Medof M. E. Decay-accelerating factor protects human tumor cells from complement-mediated cytotoxicity in vitro. J. Clin. Invest., 81: 1122-1128, 1988.
  37. Niehans G. A., Cherwitz D. L., Staley N. A., Knapp D. J., Dalmasso A. P. Human carcinomas variably express the complement inhibitory proteins CD46 (membrane cofactor protein), CD55 (decay-accelerating factor), and CD59 (protectin). Am. J. Pathol., 149: 129-142, 1996.[Abstract]
  38. Barratt-Boyes S. M. Making the most of mucin: a novel target for tumor immunotherapy. Cancer Immunol. Immunother., 43: 142-151, 1996.[Medline]
  39. Couto J. R., Blank E. W., Peterson J. A., Kiwan R., Padlan E. A., Ceriani R. L. Engineering of antibodies for breast cancer therapy: construction of chimeric and humanized versions of the murine monoclonal antibody BrE-3. Adv. Exp. Med. Biol., 353: 55-59, 1994.[Medline]
  40. Couto J. R., Padlan E. A., Blank E. W., Peterson J. A., Ceriani R. L. Humanization of KC4G3, an anti-human carcinoma antibody. Hybridoma, 13: 215-219, 1994.[Medline]
  41. Baker T. S., Bose C. C., Caskey-Finney H. M., King D. J., Lawson A. D., Lyons A., Mountain A., Owens R. J., Rolfe M. R., Sehdev M., Yarranton G. T., Adair J. R. Humanization of an anti-mucin antibody for breast and ovarian cancer therapy. Adv. Exp. Med. Biol., 353: 61-82, 1994.[Medline]
  42. Henderikx P., Kandilogiannaki M., Petrarca C., von Mensdorff-Pouilly S., Hilgers J. H. M., Krambovitis E., Arends J. W., Hoogenboom H. R. Human single-chain Fv antibodies to MUC1 core peptide selected from phage display libraries recognizes unique epitopes and predominantly bind adenocarcinoma. Cancer Res., 58: 4324-4332, 1998.[Abstract/Free Full Text]
  43. Liang P., Pardee A. B. Recent advances in differential display. Curr. Opin. Immunol., 7: 274-280, 1995.[Medline]
  44. Schena M., Shalon D., Davis R. W., Brown P. O. Quantitative monitoring of gene expression patterns with a complementary DNA microarray. Science (Washington DC), 270: 467-470, 1995.[Abstract/Free Full Text]
  45. DeRisi J., Penland L., Brown P. O., Bittner M. L., Meltzer P. S., Ray M., Chen Y., Su Y. A., Trent J. M. Use of a cDNA microarray to analyze gene expression patterns in human cancer. Nat. Genet., 14: 457-460, 1996.[Medline]
  46. Chee M., Yang R., Hubbell E., Berno A., Huang X. C., Stern D., Winkler J., Lockhart D. J., Morris M. S., Fodor S. P. Accessing genetic information with high-density DNA arrays. Science (Washington DC), 274: 610-614, 1996.[Abstract/Free Full Text]
  47. Velculescu V. E., Zhang L., Vogelstein B., Kinzler K. W. Serial analysis of gene expression. Science (Washington DC), 270: 484-487, 1995.[Abstract/Free Full Text]
  48. Zhang L., Zhou W., Velculescu V. E., Kern S. E., Hruban R. H., Hamilton S. R., Vogelstein B., Kinzler K. W. Gene expression profiles in normal and cancer cells. Science (Washington DC), 276: 1268-1272, 1997.[Abstract/Free Full Text]
  49. Hibi K., Liu Q., Beaudry G. A., Madden S. L., Westra W. H., Wehage S. L., Yang S. C., Heitmiller R. F., Bertelsen A. H., Sidransky D., Jen J. Serial analysis of gene expression in non-small cell lung cancer. Cancer Res., 58: 5690-5694, 1998.[Abstract/Free Full Text]
  50. Pasqualini R., Ruoslahti E. Organ targeting in vivo using phage display peptide libraries. Nature (Lond.), 380: 364-366, 1996.[Medline]
  51. Pasqualini R., Koivunen E., Ruoslahti E. {alpha}v integrins as receptors for tumor targeting by circulating ligands. Nat. Biotechnol., 15: 542-546, 1997.[Medline]
  52. Arap W., Pasqualini R., Ruoslahti E. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science (Washington DC), 279: 377-380, 1998.[Abstract/Free Full Text]



This article has been cited by other articles:


Home page
 J BiochemHome page
S. Muraoka, Y. Ito, M. Kamimura, M. Baba, N. Arima, Y. Suda, S. Hashiguchi, M. Torikai, T. Nakashima, and K. Sugimura
Effective Induction of Cell Death on Adult T-Cell Leukaemia Cells by HLA-DR{beta}-Specific Small Antibody Fragment Isolated from Human Antibody Phage Library
J. Biochem., June 1, 2009; 145(6): 799 - 810.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
S. Sharma, J. Tammela, X. Wang, H. Arnouk, D. Driscoll, P. Mhawech-Fauceglia, S. Lele, A. L. Kazim, and K. Odunsi
Characterization of a Putative Ovarian Oncogene, Elongation Factor 1{alpha}, Isolated by Panning a Synthetic Phage Display Single-Chain Variable Fragment Library with Cultured Human Ovarian Cancer Cells
Clin. Cancer Res., October 1, 2007; 13(19): 5889 - 5896.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
L. Galibert, G. S. Diemer, Z. Liu, R. S. Johnson, J. L. Smith, T. Walzer, M. R. Comeau, C. T. Rauch, M. F. Wolfson, R. A. Sorensen, et al.
Nectin-like Protein 2 Defines a Subset of T-cell Zone Dendritic Cells and Is a Ligand for Class-I-restricted T-cell-associated Molecule
J. Biol. Chem., June 10, 2005; 280(23): 21955 - 21964.
[Abstract] [Full Text] [PDF]

Home page
 Endocr Relat CancerHome page
P. Carter, L. Smith, and M. Ryan
Identification and validation of cell surface antigens for antibody targeting in oncology
Endocr. Relat. Cancer, December 1, 2004; 11(4): 659 - 687.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Pathol.Home page
K A Smith, P N Nelson, P Warren, S J Astley, P G Murray, and J Greenman
Demystified...recombinant antibodies.
J. Clin. Pathol., September 1, 2004; 57(9): 912 - 917.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
D. B. Rubinstein, A. Stortchevoi, M. Boosalis, R. Ashfaq, and T. Guillaume
Overexpression of DNA-binding Protein B Gene Product in Breast Cancer as Detected by in Vitro-generated Combinatorial Human Immunoglobulin Libraries
Cancer Res., September 1, 2002; 62(17): 4985 - 4991.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
C. De Lorenzo, D. B. Palmer, R. Piccoli, M. A. Ritter, and G. D'Alessio
A New Human Antitumor Immunoreagent Specific for ErbB2
Clin. Cancer Res., June 1, 2002; 8(6): 1710 - 1719.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
J. A. Coronella, P. Telleman, G. A. Kingsbury, T. D. Truong, S. Hays, and R. P. Junghans
Evidence for an Antigen-driven Humoral Immune Response in Medullary Ductal Breast Cancer
Cancer Res., November 1, 2001; 61(21): 7889 - 7899.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
J. L. Cyr and A. J. Hudspeth
A library of bacteriophage-displayed antibody fragments directed against proteins of the inner ear
PNAS, February 29, 2000; 97(5): 2276 - 2281.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ridgway, J. B. B.
Right arrow Articles by Carter, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ridgway, J. B. B.
Right arrow Articles by Carter, P.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online